trastuzumab
Neratinib Shows Promise in Certain Metastatic Breast Cancer Cases
A combination of neratinib, fulvestrant and trastuzumab showed encouraging clinical activity in patients with ...
MARCH 9, 2022
FDA Approves Ontruzant, Biosimilar to Herceptin
The biosimilar trastuzumab-dttb (Ontruzant, Samsung Bioepis) was approved for all eligible indications of the ...
JANUARY 22, 2019
FDA Approves Herzuma for Breast Cancer
The FDA approved Herzuma, a HER2/neu receptor antagonist biosimilar to Herceptin for breast cancer treatment.
DECEMBER 17, 2018
Has the Case Been Made for Shorter Trastuzumab Rx?
Chicago—Six months of trastuzumab is noninferior to 12 months, according to results of the large, multicenter ...
OCTOBER 5, 2018
FDA Approves Biosimilar Ogivri for Breast, Stomach Cancers
Ogivri is the first biosimilar approved in the United States for the treatment of breast cancer or stomach ...
DECEMBER 4, 2017
How I Manage Adjuvant Therapy in HER2-Positive Breast Cancer
Adjuvant anti-HER2 therapy in combination with chemotherapy has markedly improved disease-free survival and overall ...
JULY 12, 2017
Pertuzumab Plus Trastuzumab Yields Small Benefit at Steep Price
Adding pertuzumab to trastuzumab for women with HER2-positive breast cancer reduced the risk for invasive breast ...
JUNE 1, 2017
AACR Report: HER2-Targeted Rx Effective in HER2+ mCRC
In heavily pretreated patients with HER2-positive mCRC, a combination of trastuzumab and lapatinib provided ...
APRIL 6, 2017
Trial Supports ß-Blockers for Trastuzumab Toxicity
San Antonio—Using standard heart failure pharmacotherapy during treatment with trastuzumab can prevent ...
MARCH 30, 2016
